GEN Exclusives

More »

GEN News Highlights

More »
Oct 25, 2007

Glycominds and Fox Chase Cancer Center Partner to Discover Breast Cancer Diagnostic Blood Test

  • Glycominds entered into a research agreement with Fox Chase Cancer Center (FCCC) to develop a new blood test for breast cancer.

    “Glycominds’ antiglycan antibodies biomarkers approach together with FCCC’s excellent patient records, samples, and clinical know-how give this project a high basis for success,” asserts Nir Dotan, Ph.D., Glycominds’ cofounder, CTO, and vp of R&D.

    “I believe that glycan technology has the potential to enhance the early diagnosis of breast cancer,” notes Andrew K. Godwin, Ph.D., director of the clinical molecular genetics laboratory and the biosample repository at FCCC.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?